BofA Securities Upgrades Akero Therapeutics (AKRO) to Buy

BofA Securities analyst Jason Zemansky upgraded Akero Therapeutics (NASDAQ: AKRO) from Neutral to Buy with a price target of $63.00 (from $35.00).

For an analyst ratings summary and ratings history on Akero Therapeutics click here. For more ratings news on Akero Therapeutics click here.

Shares of Akero Therapeutics closed at $54.00 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• Maxis Bhd (MAXIS:MK) (MAXSF) PT Raised to MYR3.82 at Nomura/Instinet
• JD Logistics Inc (2618:HK) (JDLGF) PT Lowered to HK$18 at Nomura/Instinet